Atherosclerosis, implications structure

Plasminogen activator inhibitor-1 (PAI-1) is an endogenous serine protease inhibitor, elevated levels of which have been implicated in acute and chronic conditions, including sepsis, myocardial infarction, cancer, atherosclerosis, and type 2 diabetes. It is believed that development of therapeutic agents that are potent and selective inhibitors of PAI-1 will be beneficial in the treatment of these conditions. A variety of polyphenolic compounds have been synthesized and found to be potent inhibitors of PAI-1. The synthesis and structure-activity relationships of these compounds will be presented. 

---